8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                               ------------------

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of report (Date of earliest event reported): October 17, 2005

                              --------------------

                              PharmaFrontiers Corp.
             (Exact Name of Registrant as Specified in Its Charter)
             ------------------------------------------------------


                                      Texas
                                      -----
                 (State or Other Jurisdiction of Incorporation)

           000-25513                                     76-0333165
           ---------                                     ----------
   (Commission File Number)                 (I.R.S. Employer Identification No.)

           2635 Crescent Ridge Drive
             The Woodlands, Texas                                77381
             --------------------                                -----
   (Address of Principal Executive Offices)                    (Zip Code)

       Registrant's telephone number, including area code: (281) 272-9331

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))






Item  5.02.       Departure of Directors or Principal Officers; Election of
Directors; Appointment of Principal Officers.

         On October 17, 2005, Brooks Boveroux was elected to the Board of
Directors. Mr. Boveroux will serve on the Board's Audit Committee. Mr. Boveroux
entered into a standard director's agreement whereby he received ten year
options to purchase 52,500 shares of Company common stock at an exercise price
per share of $1.15 for agreeing to serve on the Board and the Audit Committee.
There is no other arrangement or understanding between Mr. Boveroux and any
other person pursuant to which Mr. Boveroux was selected as a director. Mr.
Boveroux has not been involved with a related transaction or relationship as
defined by Item 404(a) of Regulation S-B between the Company and him.



Item 9.01         Financial Statements and Exhibits

(c)        Exhibit 99.1

The following exhibits are to be filed as part of this 8-K:


Exhibit No.          Description

99.1                 Press release issued October 18, 2005


                                   SIGNATURES


         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                              PHARMAFRONTIERS CORP.


                              By: /s/ David B. McWilliams
                              ---------------------------
                              David B. McWilliams, Chief Executive Officer



DATE:  October 19, 2005






                                  EXHIBIT LIST

Exhibit No.          Description

99.1                 Press release issued October 18, 2005











                                  End of report

EX-99.1

                                                                    Exhibit 99.1

PharmaFrontiers Corp. Names Brooks Boveroux to Board of Directors

    THE WOODLANDS, Texas--(BUSINESS WIRE)--Oct. 18,
2005--PharmaFrontiers Corp. (OTCBB:PFTR), a company involved in the
development and commercialization of cell therapies, announced that
Brooks Boveroux has been elected to serve as a member of its board of
directors. He will also join PharmaFrontiers' audit committee. Mr.
Boveroux, age 62, has held the post of vice president of finance for
several prominent biotechnology companies including Biogen, Inc.,
ImClone Systems, Inc. and The Liposome Company, Inc. His career spans
over two decades of senior level financial positions of both public
and private companies in the health care industry and his last
position was chief financial officer of Imcor Pharmaceutical Co., a
specialty pharmaceutical company, from which he retired in 2004.
    David McWilliams, chief executive officer of PharmaFrontiers
Corp., commented, "We are pleased to have Mr. Boveroux join our board
of directors. His broad experience in finance and background in health
care and pharmaceutical organizations will add significant value and
insight to the board."
    Mr. Boveroux received a Bachelor of Arts in English Literature
from Hamilton College and a Masters of Business Administration in
Finance from the Wharton Graduate Division, University of
Pennsylvania.

    About PharmaFrontiers Corp.

    PharmaFrontiers' strategy is to develop and commercialize cell
therapies to treat several major disease areas such as cardiac and
pancreatic conditions and Multiple Sclerosis. PharmaFrontiers owns
patented and proprietary individualized cell therapies that are in FDA
Phase I/II human dose ranging clinical trials to evaluate their safety
and effectiveness in treating MS. The company also holds the exclusive
worldwide license from the University of Chicago, through its prime
contractor relationship with Argonne National Laboratory, for patents
relating to the use of adult pluripotent stem cells derived from
patients' own circulating blood.

    Safe Harbor Statement

    This press release contains "forward-looking statements,"
including statements about PharmaFrontiers' growth and future
operating results, discovery and development of products, strategic
alliances and intellectual property, as well as other matters that are
not historical facts or information. These forward-looking statements
are based on management's current assumptions and expectations and
involve risks, uncertainties and other important factors, specifically
including those relating to PharmaFrontiers' ability to obtain
additional funding, develop its stem cell technologies, achieve its
operational objectives and obtain patent protection for its
discoveries that may cause PharmaFrontiers' actual results to be
materially different from any future results expressed or implied by
such forward-looking statements. PharmaFrontiers undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or otherwise.

    CONTACT: PharmaFrontiers Corp.
             C. William Rouse, 281-775-0608
             brouse@pharmafrontierscorp.com
             or
             Investor Relations Contacts:
             Lippert/Heilshorn & Associates
             Kim Sutton Golodetz, 212-838-3777
             kgolodetz@lhai.com
             Bruce Voss, 310-691-7100
             bvoss@lhai.com
             or
             Media Relations Contact:
             Lippert/Heilshorn & Associates
             Mark Stuart, 310-691-7100
             mstuart@lhai.com